TP53 and cancer: An important aspect of the present study is the demonstration that an IRE1 inhibitor STF-083010 selectively inhibited the growth of tumors induced by p53-null human cancer cells in nude mice, suggesting that IRE1 inhibitors may serve as anticancer drugs that target mutant forms of p53.